- Home
- RNAZ vs EVOK Comparison
RNAZ vs EVOK Comparison
Compare RNAZ & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- EVOK
- Stock Information
- Founded
- RNAZ 2016
- EVOK 2007
- Country
- RNAZ United States
- EVOK United States
- Employees
- RNAZ N/A
- EVOK N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- RNAZ Health Care
- EVOK Health Care
- Exchange
- RNAZ Nasdaq
- EVOK Nasdaq
- Market Cap
- RNAZ 6.1M
- EVOK 5.4M
- IPO Year
- RNAZ 2021
- EVOK 2013
- Fundamental
- Price
- RNAZ $11.51
- EVOK $4.99
- Analyst Decision
- RNAZ Strong Buy
- EVOK
- Analyst Count
- RNAZ 1
- EVOK 0
- Target Price
- RNAZ $280.00
- EVOK N/A
- AVG Volume (30 Days)
- RNAZ 251.6K
- EVOK 116.9K
- Earning Date
- RNAZ 08-22-2025
- EVOK 08-19-2025
- Dividend Yield
- RNAZ N/A
- EVOK N/A
- EPS Growth
- RNAZ N/A
- EVOK N/A
- EPS
- RNAZ N/A
- EVOK N/A
- Revenue
- RNAZ N/A
- EVOK $11,594,083.00
- Revenue This Year
- RNAZ N/A
- EVOK $57.82
- Revenue Next Year
- RNAZ N/A
- EVOK $59.12
- P/E Ratio
- RNAZ N/A
- EVOK N/A
- Revenue Growth
- RNAZ N/A
- EVOK 89.89
- 52 Week Low
- RNAZ $6.15
- EVOK $1.94
- 52 Week High
- RNAZ $739.20
- EVOK $12.32
- Technical
- Relative Strength Index (RSI)
- RNAZ 56.95
- EVOK 54.42
- Support Level
- RNAZ $10.16
- EVOK $5.33
- Resistance Level
- RNAZ $12.10
- EVOK $5.70
- Average True Range (ATR)
- RNAZ 1.40
- EVOK 0.49
- MACD
- RNAZ -0.11
- EVOK 0.03
- Stochastic Oscillator
- RNAZ 23.51
- EVOK 65.55
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.